Glowing, biofluorescent fish originated over a hundred million years ago
Biofluorescence is where a living organism can absorb light before letting it out again. The result is the creatures seem to glow with different colours and even patterns. It is different to bioluminescence which is when the creatures create the light inside themselves and so can glow in total darkness. The researchers produced a list of 459 biofluorescent species, including 48 species that were not previously known to be biofluorescent.They also estimated the biofluorescence dated back about 112 million years, with the first instance happening in eels.The team also found that fish species that live in or around coral reefs evolve biofluorescence faster than those that live outside of the reef. Most of the species studied were associated with coral reefs.
The researchers found there was a sharp increase in glowing species after the dinosaurs became extinct 66 million years ago.This was also when there was a rise of modern coral-dominated reefs which the study authors say could explain the sudden surge of biofluorescence.For the second study, published in PLOS One, the scientists looked at fish they already knew were biofluorescent under special lights.The researchers were surprised by the range of colours with some species giving out several colours and patterns.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
2 hours ago
- The Independent
Scientists identify cause of sea star epidemic along North America's Pacific coast
Scientists have identified a specific bacterium, Vibrio pectenicida, as the cause of the devastating sea star wasting disease that has killed over five billion sea stars off North America's Pacific coast since 2013. The disease, which causes lesions and arm loss, has severely impacted over 20 species, with the sunflower sea star losing approximately 90 percent of its population within five years. The breakthrough, published in Nature Ecology and Evolution, involved meticulously analyzing the coelomic fluid of sea stars, overcoming previous false leads that focused on dead tissue samples. Identifying the bacterium provides a crucial step for intervention, allowing scientists to test remaining sea stars, consider relocation or captive breeding, and investigate natural immunity or probiotic treatments. The recovery of sea star populations is vital for the Pacific ecosystem, as their decline led to an explosion in sea urchins, which subsequently decimated 95 percent of Northern California 's kelp forests.
Reuters
2 hours ago
- Reuters
Vertex's trial failure, scrapped study cloud pain drug push; shares slump
Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of its approved pain drug, sending its shares down 14.4% after the bell. The company (VRTX.O), opens new tab has been diversifying into gene therapies and non-opioid painkillers as it looks to reduce its reliance on cystic fibrosis drugs, a market it dominates. Unlike opioids, which trigger the brain's reward centers, making them an addiction risk, Vertex's drugs block pain signals at the origin, providing a lucrative opportunity for the company. The next-generation non-opioid painkiller, called VX-993, reduced pain by 74.5 points over 48 hours, compared with 50.2 points in the placebo group, but the difference was not statistically significant, Vertex said. The company tested acute pain reduction in patients who had bunionectomy, a surgery to correct deformed bones of the big toe and foot. The drug was found to be generally safe, with most side effects being mild to moderate and no serious problems linked to the painkiller, the company said. Wall Street analysts and investors have been keenly watching the results of the trial, as Vertex seeks to expand beyond Journavx, its non-opioid approved by the U.S. Food and Drug Administration in January for acute pain. Separately, Vertex also said it would not start a study for Journavx to treat a type of nerve pain in the lower back and legs following discussion with the FDA. Leerink Partners analyst David Risinger said Vertex's pain portfolio updates were "disappointing," despite reporting second-quarter results that were above expectations. Vertex plans to prioritize testing of, and later seeking approval for, Journavx to treat a type of nerve pain in diabetic patients. It will also seek to secure approval for other types of nerve pain, the company said in its earnings press release.
The Independent
4 hours ago
- The Independent
NASA's Curiosity rover can now multitask
NASA 's Curiosity rover, which landed on Mars 13 years ago, has been equipped with significant new capabilities. These upgrades allow the rover to multitask, performing scientific activities while simultaneously conserving energy from its nuclear battery. Curiosity can now communicate with an orbiter, drive, move its robotic arm, and capture images concurrently. The rover can also autonomously decide to power down early if its daily tasks are completed, reducing the need for extensive recharging. These enhancements aim to maximize the lifespan of its power source, as Curiosity continues to explore Martian geological formations believed to be formed by ancient water.
